Business
Amphastar Pharmaceuticals Reports Financial Results for the Three Months and Full-Year Ended December 31, 2022
Reports Net Revenues of $135.0 Million for the Three Months Ended December 31, 2022RANCHO CUCAMONGA, CA / ACCESSWIRE / February 28, 2023 / Amphastar
About this update from Amphastar Pharmaceuticals, Inc.
[{"type":"text","content":"Reports Net Revenues of $135.0 Million for the Three Months Ended December 31, 2022RANCHO CUCAMONGA, CA / ACCESSWIRE / February 28, 2023 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) (\"Amphastar\" or the \"Company\") today reported results for the three months and full-year ended December 31, 2022.Fourth Quarter HighlightsNet revenues of $135.0 million for the fourth quarterGAAP net income of $33.9 million, or $0.66 per share, for the fourth quarterAdjusted non-GAAP net income of $37.6 million, or $0.73 per share, for the fourth quarterFull-Year HighlightsNet revenues of $499.0 million for the fiscal yearGAAP net income of $91.4 million, or $1.74 per share, for the fiscal yearAdjusted non-GAAP net income of $103.2 million, or $1.97 per share, for the fiscal yearDr. Jack Zhang, Amphastar's President and Chief Executive Officer, commented: \"We are pleased to report our strongest quarter yet, driven by sales of epinephrine, Primatene MIST®, glucagon, and other finished pharmaceutical products. Looking ahead to 2023, we anticipate launching multiple new products to continue driving our growth.\" Three Months Ended Year Ended December 31, December 31, 2022 2021 2022 2021 (in thousands, except per share data) Net revenues $135,023 $120,887 $498,987 $437,768 GAAP net income attributable to Amphastar $33,913 $19,760 $91,386 $62,116 Adjusted non-GAAP net income attributable to Amphastar* $37,638 $20,833 $103,186 $67,999 GAAP diluted EPS attributable to Amphastar stockholders $0.66 $0.39 $1.74 $1.25 Adjusted non-GAAP diluted EPS attributable to Amphastar stockholders* $0.73 $0.42 $1.97 $1.37 * Adjusted non-GAAP net income attributable to Amphastar and Adjusted non-GAAP diluted EPS attributable to Amphastar stockholders are non-GAAP financial measures. Please see the discussion in the section entitled \"Non-GAAP Financial Measures\" and the reconciliation of GAAP to non-GAAP financial measures in Table III of this press release.Fourth Quarter Results Three Months Ended December 31, Change 2022 2021 Dollars % (in thousands) Net revenues: Primatene MIST® $22,279 $21,489 $790 4%Epinephrine 21,427 18,868 2,559 14%Glucagon 18,319 15,335 2,984 19%Lidocaine 13,286 12,099 1,187 10%Phytonadione 11,666 13,921 (2,255) (16)%Enoxaparin 7,812 7,942 (130) (2)%Naloxone 4,845 6,546 (1,701) (26)%Other finished pharmaceutical products 33,082 21,776 11,30...